Table II.

Changes in atopic dermatitis-associated parameters after 16 weeks dupilumab treatment following adjustment for clinical findings

Characteristics	Coefficient	95% CI	p-value
Total Eczema Area and Severity Index
Week	–1.25	–1.39, –1.10	< 0.001
Clinical findings
General type	Reference
Facial type	5.34	1.02, 9.66	0.015
Prurigo type	5.04	–1.56, 11.63	0.134
Head and Neck Eczema Area and Severity Index
Week	–0.12	–0.14, –0.11	< 0.001
Clinical findings
General type	Reference
Facial type	0.62	0.12, 1.11	0.015
Prurigo type	–0.73	–1.51, 0.05	0.066
Patient-Oriented Eczema Measure
Week	–0.74	–0.82, –0.65	< 0.001
Clinical findings
General type	Reference
Facial type	1.09	–0.90, 3.07	0.283
Prurigo type	0.01	–2.99, 3.00	0.996
Itch Numerical Rating Scale
Week	–0.26	–0.30, –0.22	< 0.001
Clinical findings
General type	Reference
Facial type	–0.32	–1.06, 0.42	0.401
Prurigo type	0.06	–1.04, 1.16	0.915

95% CI: 95% confidence interval.